A particularly compelling study would be a head-to-head comparison of SGLT2is versus beta-blockers or ACE inhibitors in patients with stable ischemic heart disease, assessing whether SGLT2is could reduce angina burden, improve exercise tolerance, or lower the need for revascularization procedures. The gene discussed is ACE; the disease is coronary artery disorder.